Key Highlights

  • ALGN shares fell approximately 6% in pre-market trading to $169.00, down from a prior close of $180.08.
  • Second-quarter revenue reached a record $1.06 billion, up 4.3% year over year and modestly ahead of the $1.052 billion estimate.
  • Third-quarter revenue guidance of $1.00 billion to $1.02 billion came in below the $1.024 billion consensus.
  • The company increased its 2026 share buyback authorization to $400 million to $500 million following engagement with activist investor Elliott Investment Management.

Cautious Guidance Overshadows Record Quarter

Align Technology, Inc. (NASDAQ:ALGN) shares fell in pre-market trading despite the company reporting record second-quarter revenue, as investors focused on a soft forward outlook. Align is a Tempe, Arizona-based global medical device company that designs and markets the industry-leading Invisalign clear aligner system alongside iTero digital intraoral scanners, serving orthodontists, general dentists, and restorative dental professionals across more than 100 markets.

Second-quarter clear aligner volumes hit a record 692,000 cases, up 7.4% year over year, with clear aligner revenue up 8.2% and non-GAAP operating margin exceeding expectations at 22.9%. Despite these results, third-quarter guidance of $1.00 billion to $1.02 billion in revenue fell short of the $1.024 billion consensus, with management citing continued pricing pressure from a shift toward lower-cost scanner configurations, leasing, and rental models within the Systems and Services segment.

Governance Changes Follow Activist Engagement

Following discussions with activist investor Elliott Investment Management, Align announced plans to add three new independent board directors and launch a comprehensive strategic and operating model review with a global consulting firm. The company also increased its 2026 share repurchase authorization to a range of $400 million to $500 million, up from its prior authorization, though these initiatives were not enough to offset investor focus on decelerating growth and margin pressure ahead.

Align also disclosed that a UK Upper Tribunal ruling overturned a prior determination that clear aligners qualify as VAT-exempt, resulting in a $37.5 million estimated liability and the introduction of a 20% UK VAT effective September 7, which the company plans to appeal while keeping list prices unchanged. Align carries a market capitalization of approximately $12.90 billion following the pre-market decline, with shares trading within a 52-week range of $122.00 to $207.08.

Conclusion

Today's decline illustrates how forward guidance can outweigh a record quarter and new capital-return initiatives when the outlook signals decelerating growth, even alongside meaningful governance changes following activist engagement. Investors will likely watch the completion of the strategic and operating model review, along with third-quarter results, for further clarity on the company's path forward.

This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.